Skip to main content
IOVA
NASDAQ Life Sciences

Iovance Posts Record Q2 Revenue of ~$99M, Gross Margin Hits 56%, and FDA Grants Fast Track for Lifileucel in Sarcomas

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$4.941
Mkt Cap
$1.938B
52W Low
$1.76
52W High
$5.64
52W Position info
181% above low
Off High info
12% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

IOVA has more than doubled off its 52-week low of $1.76.

Summary

Iovance reported record Q2 2026 revenue of ~$99M, a 66% increase, with gross margin reaching 56%. The company is reviewing its full-year guidance upward and announced FDA Fast Track for lifileucel in soft tissue sarcomas. Cash of ~$304M funds operations into 2H28.

Updates

  1. · SEC 10-Q — Q2 net loss was $47.3M, or $0.11 per share, compared with $111.7M, or $0.33 per share, a year earlier. Six-month revenue was $170.7M and net loss $126.4M.


Key Events · Earnings and Guidance · IOVA

  • Record Q2 Revenue

    Total product revenue reached ~$99M, up 66% from ~$60M in Q2 2025, driven by U.S. Amtagvi sales of ~$91M.

  • Gross Margin Expansion

    Gross margin improved to 56%, reflecting higher sales volume, cost optimization, and manufacturing efficiencies.

  • Guidance Under Review

    Based on strong Q2 performance, Iovance is reviewing its FY2026 revenue guidance of $350M-$370M and will provide an update in Q3.

  • FDA Fast Track for Sarcomas

    FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas, supporting the registrational SARATOGA trial in UPS and DDLPS.


Analysis · IOVA · Life Sciences

Iovance delivered its strongest quarter yet, with Amtagvi driving U.S. revenue to ~$91M and total revenue up 66% year-over-year. Gross margin jumped to 56%, reflecting manufacturing efficiencies and cost discipline. The company is reviewing its full-year guidance of $350M-$370M, signaling potential upside. FDA Fast Track designation for lifileucel in soft tissue sarcomas opens a new registrational path, while a cash runway into 2H28 removes near-term financing risk. This quarter marks a turning point toward profitability and pipeline expansion.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IOVA was trading at $4.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $1.76 to $5.64. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IOVA - Latest Insights

IOVA
Nov 05, 2026, 9:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $8.05 info
Change: -$0.3881 (-5%) info
Market Cap: $3.642B info
IOVA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $9.24
Real-time Price: $8.05 info
Change: -$1.19 (-13%) info
Market Cap: $3.642B info
IOVA
Oct 29, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $9.38
Real-time Price: $8.05 info
Change: -$1.33 (-14%) info
Market Cap: $3.642B info
IOVA
Oct 29, 2026, 3:11 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $9.69
Real-time Price: $8.05 info
Change: -$1.64 (-17%) info
Market Cap: $3.642B info
IOVA
Oct 29, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.13
Real-time Price: $8.05 info
Change: -$5.08 (-39%) info
Market Cap: $3.642B info